#USA #San Diego #RNA Therapeutics #Avidity Biosciences #AOCs

Avidity Biosciences to Engage with Investors

Avidity Biosciences, Inc. (Nasdaq: RNA), a leading biopharmaceutical company, recently announced its participation in multiple upcoming investor conferences, aiming to share insights into its innovative RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™). The company is set to present its advancements at three prominent health care conferences next month.

Key Conference Dates

• - TD Cowen 45th Annual Health Care Conference: March 4, 2025, at 3:10 p.m. ET
• - Leerink Partners Global Healthcare Conference: March 11, 2025, at 1:00 p.m. ET
• - Barclays 27th Annual Global Healthcare Conference: March 12, 2025, at 11:30 a.m. ET

During these events, Avidity will conduct a fireside chat which will delve into their ongoing commitment to revolutionize treatments for neuromuscular diseases. Attendees can access live webcasts of each presentation via Avidity's 'Events and Presentations' page on their official website, where they will also find the latest event details and previously recorded discussions.

Avidity's Mission and Innovations

Avidity Biosciences is focused on developing a new class of RNA therapies, with its AOCs designed to effectively combine the specificity of monoclonal antibodies with the therapeutic potency of oligonucleotide drugs. This exciting approach is positioned to address medical conditions that were previously thought to be unreachable using traditional RNA therapies.

The company's proprietary AOC platform has already succeeded in demonstrating the high-precision delivery of RNA directly into muscle cells, marking a significant milestone in the treatment of rare neuromuscular disorders. Avidity is actively pursuing clinical development for three key conditions: Myotonic Dystrophy Type 1 (DM1), Duchenne Muscular Dystrophy (DMD), and Facioscapulohumeral Muscular Dystrophy (FSHD).

In addition to its neuromuscular disease programs, Avidity is expanding its focus on cardiac health with two proprietary therapeutic candidates aimed at addressing rare genetic cardiomyopathies. This expansion showcases Avidity's commitment to broadening the application of its AOC technology beyond neuromuscular conditions and into other critical areas of medicine including cardiology and immunology.

Looking Forward

Avidity's involvement in these conferences not only highlights its dedication to advancing RNA science but also emphasizes the importance of engaging with the investment community to foster support for its groundbreaking work. The company urges all interested stakeholders to tune into their presentations, where they will highlight both their innovative strategies and the remarkable potential of RNA therapeutics.

For further information on Avidity’s AOC platform, ongoing clinical trials, and to stay updated on their latest initiatives, visit their website or connect through social media platforms like LinkedIn and X.

As Avidity Biosciences continues on its path to transform RNA therapeutics, its participation in these key investor conferences underscores its role as a pioneer in developing solutions that could significantly improve the lives of patients suffering from rare and debilitating diseases.